Researchers have identified over 4,000 nanomedical clinical trials in progress now, highlighting rapid growth in the field and the need for a standardized lexicon to support clinical translation and collaboration.
Nanotechnology is the science of materials at the nanoscale, where matter behaves differently than it does at larger scales. The unique properties at this size have enabled the development of advanced tools for drug delivery, diagnostics, and therapeutics, tools that can significantly improve how diseases are detected and treated.
When applied to healthcare, nanotechnology has the potential to enhance treatment precision, reduce side effects, and increase therapeutic efficacy. With the help of specialized nanocarriers like liposomes, polymeric nanoparticles, or metallic nanoparticles, clinicians are better equipped to target specific tissues or cells.
However, for researchers to work collaboratively and for findings to be translatable across the globe, a standardized way to understand and unpick scientific work in nanomedicine is required. A recent review published in Nano Today hopes to kickstart a lexicon to do just that.
The Landscape of Nanomedical Trials
To assess the clinical integration of nanotechnology, the researchers analyzed over 500,000 studies from the Aggregate Analysis of ClinicalTrials.gov (AACT) database. Using a novel lexicon built with expert input and generative AI, they picked out 4,114 nanomedical trials spanning various conditions and therapeutic approaches.
Their standardizing lexicon was developed in multiple stages. Experts first created a foundation of terminology, which was expanded using AI-based tools and refined through iterative review. Researchers then used PostgreSQL and Python to extract data on each trial’s registration year, phase, intervention type, and associated medical condition.
This methodology enabled the team to classify a complex and evolving clinical landscape, offering insights into how and where nanotechnology is being applied across medicine.
Trends, Growth, and Ongoing Challenges
The analysis revealed a 38 % increase in nanomedical clinical trials in recent years, reflecting growing interest and investment in this space. Oncology remains the dominant focus, accounting for nearly a third of the trials. However, applications are broadening, with notable activity in infectious diseases, respiratory conditions, and neurological disorders.
There is also increasing diversification in the types of nanocarriers being explored, as researchers seek to improve drug delivery strategies and therapeutic outcomes. But despite this momentum, nanomedical trials still make up less than 1 % of all registered studies.
The field faces several challenges that may explain this discrepancy. Regulatory frameworks for nanomedicine are still maturing, production costs remain high, and designing clinical trials for such complex technologies can be difficult.
One of the study’s key recommendations is the adoption of a universally accepted nanomedical lexicon. Standardized terminology would improve data harmonization and facilitate interdisciplinary collaboration, as well as help streamline regulatory processes. These steps are critical if science is to bring nanomedicine into broader clinical use.
The majority of the trials identified in the review are still in early phases, indicating that much of the field remains in exploratory or proof-of-concept stages. Advancing more studies to late-phase trials will be essential to demonstrating long-term safety and efficacy.
Clinical Potential and Real-World Impact
The study reinforces nanomedicine’s practical value in areas such as targeted cancer treatment, vaccine development, and advanced diagnostics. The response to COVID-19 highlighted the adaptability of nanomedical platforms, with 505 trials focused on mRNA vaccine technologies. This suggests an expanding scope that now includes respiratory infections, HIV, and other pressing global health concerns.
Integrating AI into lexicon development may help to enhance the accuracy of trial classification and support clearer communication among researchers, clinicians, and regulatory agencies. As more multifunctional nanomedicines, such as theranostic agents that combine therapy and diagnostics, enter development, the potential for personalized treatment and real-time monitoring continues to grow.
Looking Ahead: Collaboration and Standardization
The review emphasizes the need for continued interdisciplinary collaboration for nanomedicine to flourish to its full potential. Establishing consistent terminology is not a technical exercise—it lays the foundation for improved communication, regulatory alignment, and clinical adoption.
Another key step is to address existing barriers like high production costs and trial design complexity. Future work in nanomedicine will focus on developing new tools, including integrating advanced machine learning techniques, to accelerate product development and optimization. Efforts are also being made to design multifunctional nanomedicines capable of adapting to individual patient needs and providing real-time therapeutic feedback.
As the field evolves, coordinated efforts between scientists, healthcare professionals, and regulatory bodies are essential for ensuring nanotechnology meaningfully enhances patient care.
Journal Reference
Gultepe, E., & et al. (2025). The landscape of nanomedical clinical trials. nanotoday, 66(102898). DOI: 10.1016/j.nantod.2025.102898, https://www.sciencedirect.com/science/article/pii/S1748013225002701
News
FDA approves breakthrough drug to treat advanced pancreatic cancer
The Food and Drug Administration (FDA) approved on Wednesday a drug that could extend the survival of those with metastatic pancreatic cancer. The drug, called daraxonrasib, will be sold under the brand name Rasonque [...]
AI Decodes a Hidden DNA Signal Linked to Disease-Causing Mutations
Machine learning identifies the likely “initiator” and enables new predictions about DNA mutations that can cause disease. Every human cell depends on tens of thousands of genes being switched on at the right time [...]
Pope Leo Urges Global Response to Congo’s Deadliest Ebola Outbreak
Pope Leo called for international action to address the Ebola outbreak in the Democratic Republic of Congo. The epidemic has claimed over 2,500 lives and is the nation's largest recorded outbreak. The Pope emphasized [...]
Is there a summer COVID-19 surge this year? Yep, it’s ramping up again
Hantavirus. Ebola. West Nile. Measles. And, of course, cyclospora — that stomach parasite making people miserable across the country. Americans have plenty to worry about this summer. But remember COVID-19? It may not be [...]
Natural Compound in Broccoli Could Help Treat a Rare, Incurable Neurological Disease
Swinburne researchers have discovered how broccoli could help treat an extremely rare and incurable disease that affects only about 200 Australians. A naturally occurring compound in broccoli is being investigated as a possible treatment [...]
Antibody recycling, FcRn and the next generation of biologics
FcRn plays a central role in regulating the half-life of IgG antibodies and albumin, making it a critical target in both antibody engineering and autoimmune disease therapy. This article explores the biology of FcRn, [...]
Ebola kills 2,300 in three months with no vaccine available for Congo’s deadliest ever outbreak
It’s Congo’s 17th outbreak, with a toll that has eclipsed that of the country’s 2018-2020 outbreak when 2,299 deaths out of 3,481 cases were recorded. The latest data shows 101 new cases and 33 [...]
Beyond an Agency: How AI, Creativity and Commercialization Are Converging Into a New Growth Model
At a moment when AI is forcing a fundamental rethink of how work gets done, the life sciences industry is grappling with a deeper question: what role should human creativity play in an increasingly [...]
New $60 Blood Test Detects Lung Cancer Without Costly DNA Sequencing
A simple blood test that detects chemical changes in DNA identified more than 90% of stage 2-4 lung cancers in an early study, without relying on costly DNA sequencing. Researchers at Tel Aviv University and collaborating [...]
Reducing drug development failures with human-relevant models and AI
Professor Joseph C. Wu of Stanford University explains how stem cells, human-relevant models and AI are helping researchers predict which drug candidates are most likely to succeed before clinical trials. Researchers now have access [...]
Half of vaccines are binned – ‘fridge-free’ versions could change that
Vaccines that do not need to be kept cool in a fridge have been successfully trialed in patients for the first time, say UK scientists. Currently, most vaccines need to be refrigerated or frozen [...]
Mushroom Mystery: The Fungus That Makes People See Tiny Humans
A mushroom sold in markets and served in restaurants in Southwest China has an unusual warning attached to it: cook it thoroughly, or you may start seeing tiny people. For decades, people have reported [...]
Artificial intelligence used to design brand new viruses
Artificial Intelligence has been used to design brand new viruses that are fully functional and can replicate in the laboratory, say US researchers. It is the first time whole genomes have been successfully designed [...]
Molecular Manufacturing: The Future of Nanomedicine – New book from NanoappsMedical Inc.
This book explores the revolutionary potential of atomically precise manufacturing technologies to transform global healthcare, as well as practically every other sector across society. This forward-thinking volume examines how envisaged Factory@Home systems might enable the cost-effective [...]
Moderna kicks off Phase I Ebola trial as Africa readies itself for research
If the Phase I trial is successful, Moderna plans to quickly initiate Phase II and Phase III trials of its Ebola vaccine. Moderna has initiated a Phase I trial of its mRNA Ebola vaccine [...]
3D Human Brain Tissue Model Replicates Alzheimer’s Pathology
Summary: Researchers introduced a highly reproducible three-dimensional human brain tissue model capable of replicating complex neurodegenerative processes in Alzheimer’s disease. Developed over nine years using human stem cells, the self-organizing tissue spheroids integrate functional neurons, [...]
